–
Larimar Therapeutics, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
millions USD
FY21:
FY22:
–
FY23:
–
FY24:
–
FY25:
–
(positive)
Change from FY21 to FY25
millions USD
FY21:
−50.5
FY22:
−36.5
FY23:
−41.8
FY24:
−90.9
FY25:
−172
(positive)
Change from FY21 to FY25
millions USD
FY21:
−50.1
FY22:
−36.2
FY23:
−41.4
FY24:
−90.6
FY25:
−172
(positive)
Change from FY21 to FY25
millions USD
FY21:
−50.6
FY22:
−35.4
FY23:
−36.9
FY24:
−80.6
FY25:
−166
(positive)
Change from FY21 to FY25
millions USD
FY21:
−50.6
FY22:
−35.4
FY23:
−36.9
FY24:
−80.6
FY25:
−166
All amounts in millions USD